Titan Pharmaceuticals Inc

Titan Pharmaceuticals — Investor Presentation (October 2015)

23 slides from Titan Pharmaceuticals's investor presentation, Oct 7, 2015

  1. Slide 1: Corporate Presentation

    Corporate Presentation Sunil Bhonsle Oct 2015

  2. Slide 2: Forward-Looking Statements

    Forward - Looking Statements The presentation may contain “forward - looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Reference is made in particular to the description of our plans and objectives for future o

  3. Slide 3: Company Overview

    Company Overview Titan Pharmaceuticals specializes in the development of treatments for select chronic diseases utilizing its proprietary ProNeura ™ technology platform • ProNeura: Proprietary Long - term Drug Delivery Platform • Provides continuous drug release and non - fluctuating medication leve

  4. Slide 4: The Epidemic of Opioid Addiction

    The Epidemic of Opioid Addiction • Increasingly recognized as a global epidemic by world health authorities • Addiction - a primary, chronic disease of brain reward, motivation, memory and neurobiological circuitry • Cravings, accompanied by lack of impulse control • Abstinence is rarely a successfu

  5. Slide 5: Opioid Addiction: Treatment Overview

    Opioid Addiction: Treatment Overview Buprenorphine is the Gold Standard in the U.S., Replacing Methadone • Buprenorphine pharmacology makes it an effective, safer and more convenient treatment option • Controls withdrawal symptoms and cravings without inducing opioid euphoria in patients • Convenien

  6. Slide 6: Treatment of Opioid Addiction: Expanding the Market

    Sources : IMS Health, Wolters Kluwer Treatment of Opioid Addiction: Expanding the Market • Buprenorphine is the gold standard in the U.S ., replacing methadone • U.S. sales of daily oral formulations approximately $1.7B in 2014 • U.S. prescriptions have exceeded methadone since 2006 • M arket growth

  7. Slide 7: Proprietary ProNeura Technology: Probuphine Implant

    Buprenorphine Probuphine EVA polymer Proprietary ProNeura Technology: Probuphine Implant • Implant contains 80 mg of buprenorphine HCl, uniformly distributed throughout the ethylene vinyl acetate co - polymer (EVA) matrix • No reservoir, therefore no risk of drug dumping • Probuphine implant is inse

  8. Slide 8: Probuphine Value Proposition

    Probuphine Value Proposition Probuphine is the first and only potential treatment for opioid dependence that provides non - fluctuating blood levels of buprenorphine around - the - clock for a period of six months 8 Titan Pharmaceuticals Company Overview | Proprietary & Confidential | ©2014 Titan Ph

  9. Slide 9: Probuphine Clinical and Regulatory History

    • Six clinical studies completed and NDA submitted in October 2012 • Initial small dose finding study • Two well controlled Phase 3 safety and efficacy studies showing clinical and statistical superiority over placebo and non - inferiority to Suboxone published in Journal of American Medical Associa

  10. Slide 10: FDA-Requested Phase 3 Clinical Study Completed (PRO-814)

    FDA - Requested Phase 3 Clinical Study Completed (PRO 814) Randomized , double blind and double dummy design. Primary efficacy endpoint based on a non - inferiority comparison of ‘responders’ following six months of treatment with either a dose of four Probuphine implants or treatment with 8 mg or l

  11. Slide 11: Positive Topline Phase 3 Study Results

    Positive Topline Phase 3 Study Results Titan Pharmaceuticals Company Overview | Proprietary & Confidential | ©2014 Titan Pharmaceutical, Inc. 11 • 177 subjects randomized in the study and 173 subjects were included in the ITT population; 84 in the Probuphine arm and 89 in the sublingual buprenorphin

  12. Slide 12: Positive Topline Phase 3 Study Results

    Positive Topline Phase 3 Study Results • Sequential superiority analysis indicated a statistically significant difference in favor of Probuphine over the sublingual buprenorphine/naloxone treatment arms (p< 0.05) • Number of subjects with all six months testing negative for urines with no evidence o

  13. Slide 13: Probuphine: The First of its Kind

    Probuphine : The First of its Kind • NDA resubmitted at the end of August, 2015 and FDA has accepted the NDA for review and set an action date of February 27, 2016 • Partnership with Braeburn Pharmaceuticals for development and commercialization in U.S. and Canada • Upfront: $15.75 mil; Approval: $1

  14. Slide 14: Titan: Adding Value Beyond Probuphine

    Titan: Adding Value Beyond Probuphine Proprietary ProNeura Technology Platform • Long - term drug delivery technology validated through the Probuphine program • Potential for the treatment of select chronic diseases for which low dose, long - term delivery and stable drug levels may offer advantages

  15. Slide 15: Parkinson's Disease Overview

    . Titan Pharmaceuticals Company Overview | Proprietary & Confidential | ©2014 Titan Pharmaceutical, Inc. 15 Definition Characterized by the loss of dopamine, which alters activity in the brain region impacting movement and motor function. Treatment Treated with drugs designed to replace or mimic dop

  16. Slide 16: Parkinson's Disease Population Increasing Worldwide

    Parkinson’s Disease Population Increasing Worldwide 16 Based on information from Titan and other sources believed to be reliable and prepared exclusively for Titan. Woodside Capita l P artners is not responsible for any use that Titan may make of this material. Titan Pharmaceuticals Company Overview

  17. Slide 17: Parkinson's Disease - Therapeutics Market

    Parkinson’s Disease - Therapeutics Market • As many as one million people in the US affected by Parkinson’s disease • The number is expected to almost double by 2030 because of the aging population • About 60,000 newly diagnosed for Parkinson’s disease annually • More than 23,000 die from Parkinson’

  18. Slide 18: ProNeura Parkinson's Disease Program Non-clinical Proof of Concept

    ProNeura Parkinson’s Disease Program Non - clinical Proof of Concept • Ropinirole (Requip ® ), a dopamine agonist marketed by GSK for PD, was evaluated in a non - clinical Parkinsonian primate model using ProNeura implant technology • Results demonstrated: • Sustained plasma ropinirole levels for se

  19. Slide 19: ProNeura Parkinson's Disease Program Next Steps

    ProNeura Parkinson’s Disease Program Next Steps In consultation with our scientific advisors: • Optimize implant formulation for sustained release of ropinirole • Conduct non - clinical studies to support Investigational New Drug (IND) application • Design a proof - of - concept, first - in - human

  20. Slide 20: ProNeura: Building a Product Pipeline

    ProNeura : Building a Product Pipeline • The ProNeura platform is ideal for the treatment of select chronic diseases for which low dose, long - term treatment with stable drug levels may offer advantages over oral administration. Potential diseases include: • Hormonal Deficiencies • Type 2 Diabetes

  21. Slide 21: Titan Pharmaceuticals Summary

    Titan Pharmaceuticals Summary • Titan Pharmaceuticals specializes in the development of treatments for select chronic diseases, utilizing its innovative ProNeura technology platform • Probuphine, a six month buprenorphine implant for the maintenance treatment of opioid addiction; NDA resubmitted at

  22. Slide 22: Titan Executive Management

    • Marc Rubin, M.D, Executive Chairman and Director • Eight years with Titan Pharmaceuticals. Former Head of Global Research & Development and member of the Board of Management at Bayer Pharma. Executive R&D and commercial responsibilities at GSK for 13 years. Twenty - five years in the pharmaceutica

  23. Slide 23: Thank You

    Thank You Sunil Bhonsle Oct 2015

Titan Pharmaceuticals — Investor Presentation (October 2015) on 6ix